Menu
Recruiting NCT07622069

Diagnosis, Determining Factors, and Characteristics of Pathologies Associated With Autoinflammatory Diseases.

Observational Rare Autoinflammatory Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Rare Autoinflammatory Disease. Basic parameters: from 4 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Autoinflammatory diseases are part of a heterogeneous group of diseases that manifest themselves through an inflammatory reaction in their initial phase (innate immunity) that is activated inappropriately: either because the reaction is too strong or because it is unjustified (for example, in the absence of infection). In many cases, and in their initial description, autoinflammatory diseases have a genetic origin (and are therefore hereditary or familial) and preferentially affect children or young adults. However, a significant number of other diseases have expanded this nosological field due to the preponderance of autoinflammation in explaining the symptoms. Sometimes, autoinflammatory disease can also remain "unclassified." In general, autoinflammatory diseases manifest as recurrent attacks combining fever, skin rashes, and joint pain. Certain signs are more specific to certain diseases, such as hives, abdominal pain, mouth ulcers, or swollen lymph nodes in the neck. It is mainly the recurrence of attacks and their unprovoked nature that attract the attention of the patient and the doctor. These attacks are systematically associated with an increase in inflammatory markers in the blood. Currently, most autoinflammatory diseases are diagnosed based on a combination of clinical and biological evidence, following a thorough investigation by specialists in these diseases. Biological markers that can confirm the disease are rare. However, for some of them, confirmation can be obtained through genetic analysis. In certain cases, extensive genetic analysis may be offered. Autoinflammatory diseases are managed by specialists (internists, rheumatologists, etc.) in close collaboration with primary care physicians and other healthcare professionals (nurses, physical therapists, social workers, etc.). Treatment is sometimes based on exceptional drugs that can only be prescribed and dispensed in hospitals. This multicenter, national study, which targets children and adults with rare autoinflammatory diseases, aims to identify: * the "key" parameters for a faster diagnosis, * the determining factors and their associated characteristics, and * the treatments used and their effectiveness.

Primary outcome measures

  • Identification of etiologies related to rare autoinflammatory diseases [Time frame: 6 months after the end of the studies]

Eligibility criteria

Inclusion criteria

\- Adult patient > 18 years old Minor patient (aged 4 years and 6 months to 18 years) Patient diagnosed with a rare autoinflammatory disease Patient treated at the Hospices Civils de Lyon in the department participating in the research Patient affiliated with social security

Exclusion criteria

  • none

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Hôpital de la Croix-Rousse - Service de médecine interne - 103 Grande Rue de la Croix-Rous — Lyon

Identifiers

NCT: NCT07622069 · 25-5071

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗